portal pressure

Summary

Summary: The venous pressure measured in the PORTAL VEIN.

Top Publications

  1. ncbi Measurement of portal pressure and its role in the management of chronic liver disease
    Jaime Bosch
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut de Malalties Digestives, Hospital Clinic, IDIBAPS, University of Barcelona, Spain
    Semin Liver Dis 26:348-62. 2006
  2. ncbi Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats
    Sònia Tugues
    Department of Biochemistry and Molecular Genetics, University of Barcelona, Barcelona, Spain
    Hepatology 46:1919-26. 2007
  3. ncbi Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis
    Cristina Ripoll
    Veterans Affairs CT Healthcare System, Yale University School of Medicine, West Haven, Connecticut 06516, USA
    Gastroenterology 133:481-8. 2007
  4. ncbi Recombinant human manganese superoxide dismutase reduces liver fibrosis and portal pressure in CCl4-cirrhotic rats
    Maeva Guillaume
    Hepatic Haemodynamic Laboratory, Liver Unit, Hospital Clinic, Institut d Investigacions Biomèdiques August Pi i Sunyer IDIBAPS and Ciberehd, University of Barcelona, Spain
    J Hepatol 58:240-6. 2013
  5. ncbi Effects of probiotic therapy on portal pressure in patients with cirrhosis: a pilot study
    Puneeta Tandon
    Department of Medicine, University of Alberta, Edmonton, AB, Canada
    Liver Int 29:1110-5. 2009
  6. ncbi Correlation and comparison of the model for end-stage liver disease, portal pressure, and serum sodium for outcome prediction in patients with liver cirrhosis
    Ying Wen Wang
    Faculty of Medicine, Institute of Pharmacology, School of Medicine, National Yang Ming University, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
    J Clin Gastroenterol 41:706-12. 2007
  7. ncbi Model for end-stage liver disease score to serum sodium ratio index as a prognostic predictor and its correlation with portal pressure in patients with liver cirrhosis
    Teh Ia Huo
    Institute of Pharmacology, National Yang Ming University School of Medicine, Taipei, Taiwan
    Liver Int 27:498-506. 2007
  8. pmc Comparison of three research models of portal hypertension in mice: macroscopic, histological and portal pressure evaluation
    Anja M Geerts
    Department of Hepatology and Gastroenterology, Ghent Univerity Hospital, Ghent, Belgium
    Int J Exp Pathol 89:251-63. 2008
  9. ncbi Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg-negative chronic hepatitis B and significant portal hypertension
    Spilios Manolakopoulos
    Department of Gastroenterology, Polyclinic General Hospital, Athens, Greece
    J Hepatol 51:468-74. 2009
  10. ncbi Increased plasma malondialdehyde in patients with viral cirrhosis and its relationships to plasma nitric oxide, endotoxin, and portal pressure
    Kuei Chuan Lee
    Division of Gastroenterology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
    Dig Dis Sci 55:2077-85. 2010

Research Grants

  1. Carbamazepine for severe liver disease due to antitrypsin deficiency
    David H Perlmutter; Fiscal Year: 2012
  2. LDLT: Diagnostic Markers of Liver Regeneration to Predict Outcomes
    Elizabeth A Pomfret; Fiscal Year: 2013
  3. Molecular Mechanisms of Portal Hypertension
    Vijay H Shah; Fiscal Year: 2012
  4. A2ALL Cohort Study: Pyschosocial and Surgical Outcomes
    Abhinav Humar; Fiscal Year: 2013
  5. Quantitative Hemodynamics of the Liver with 4D Flow MRI
    Oliver Wieben; Fiscal Year: 2013
  6. CIRRHOSIS AND ITS COMPLICATIONS
    Guadalupe Garcia Tsao; Fiscal Year: 2009
  7. SPLANCHNIC HEMODYNAMICS IN PORTAL HYPERTENSION
    JAMES SITZMANN; Fiscal Year: 1992
  8. PLATELET ACTIVATING FACTOR AND THROMBOXANES IN LIVER
    Rory Fisher; Fiscal Year: 1993
  9. MODULATORY NETWORK COMPONENETS IN JAPONICA
    GLENN OLDS; Fiscal Year: 1990
  10. INTESTINE IN CHRONIC PORTAL HYPERTENSION
    JOSEPH BENOIT; Fiscal Year: 2004

Detail Information

Publications218 found, 100 shown here

  1. ncbi Measurement of portal pressure and its role in the management of chronic liver disease
    Jaime Bosch
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut de Malalties Digestives, Hospital Clinic, IDIBAPS, University of Barcelona, Spain
    Semin Liver Dis 26:348-62. 2006
    ..of portal hypertension in patients with chronic liver diseases, with special attention to the measurement of portal pressure by hepatic vein catheterization...
  2. ncbi Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats
    Sònia Tugues
    Department of Biochemistry and Molecular Genetics, University of Barcelona, Barcelona, Spain
    Hepatology 46:1919-26. 2007
    ..alpha-smooth muscle actin (alpha-SMA) accumulation, differential gene expression by microarrays, and portal pressure. Cirrhosis progression was associated with a significant enhancement of vascular density and expression of ..
  3. ncbi Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis
    Cristina Ripoll
    Veterans Affairs CT Healthcare System, Yale University School of Medicine, West Haven, Connecticut 06516, USA
    Gastroenterology 133:481-8. 2007
    ....
  4. ncbi Recombinant human manganese superoxide dismutase reduces liver fibrosis and portal pressure in CCl4-cirrhotic rats
    Maeva Guillaume
    Hepatic Haemodynamic Laboratory, Liver Unit, Hospital Clinic, Institut d Investigacions Biomèdiques August Pi i Sunyer IDIBAPS and Ciberehd, University of Barcelona, Spain
    J Hepatol 58:240-6. 2013
    ....
  5. ncbi Effects of probiotic therapy on portal pressure in patients with cirrhosis: a pilot study
    Puneeta Tandon
    Department of Medicine, University of Alberta, Edmonton, AB, Canada
    Liver Int 29:1110-5. 2009
    ..The objective of this study was to determine whether the probiotic VSL#3 would reduce portal pressure in patients with cirrhosis.
  6. ncbi Correlation and comparison of the model for end-stage liver disease, portal pressure, and serum sodium for outcome prediction in patients with liver cirrhosis
    Ying Wen Wang
    Faculty of Medicine, Institute of Pharmacology, School of Medicine, National Yang Ming University, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
    J Clin Gastroenterol 41:706-12. 2007
    ..The correlation among these markers and their predictive accuracy for survival are unclear...
  7. ncbi Model for end-stage liver disease score to serum sodium ratio index as a prognostic predictor and its correlation with portal pressure in patients with liver cirrhosis
    Teh Ia Huo
    Institute of Pharmacology, National Yang Ming University School of Medicine, Taipei, Taiwan
    Liver Int 27:498-506. 2007
    ..The models for end-stage liver disease (MELD) and serum sodium (SNa) are important prognostic markers in cirrhosis. A novel index, MELD to SNa ratio (MESO), was developed to amplify the opposing effect of MELD and SNa on outcome prediction...
  8. pmc Comparison of three research models of portal hypertension in mice: macroscopic, histological and portal pressure evaluation
    Anja M Geerts
    Department of Hepatology and Gastroenterology, Ghent Univerity Hospital, Ghent, Belgium
    Int J Exp Pathol 89:251-63. 2008
    ..A correlation was made with portal pressure measurements. Histology revealed the absence of fibrosis or cirrhosis in PPVL mice...
  9. ncbi Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg-negative chronic hepatitis B and significant portal hypertension
    Spilios Manolakopoulos
    Department of Gastroenterology, Polyclinic General Hospital, Athens, Greece
    J Hepatol 51:468-74. 2009
    Lamivudine improves liver histology in patients with chronic hepatitis B (CHB), but its effects on portal pressure remain unknown...
  10. ncbi Increased plasma malondialdehyde in patients with viral cirrhosis and its relationships to plasma nitric oxide, endotoxin, and portal pressure
    Kuei Chuan Lee
    Division of Gastroenterology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
    Dig Dis Sci 55:2077-85. 2010
    ..Increased oxidative stress is involved in the development of portal hypertension in cirrhosis. Our study aimed to assess the relationship between oxidative stress and hemodynamic parameters in cirrhotic patients...
  11. ncbi Effect of the nitric oxide donor V-PYRRO/NO on portal pressure and sinusoidal dynamics in normal and cirrhotic mice
    Claire Edwards
    Department of Medicine, Duke University Medical Center, Durham, NC, USA
    Am J Physiol Gastrointest Liver Physiol 294:G1311-7. 2008
    ..This dose decreased portal pressure in cirrhotic (23.4 +/- 2.0%, P < 0.001 vs. vehicle) and sham-treated (19.5 +/- 2.3%, P < 0.001 vs...
  12. ncbi Effects of 1-year administration of olmesartan on portal pressure and TGF-beta1 in selected patients with cirrhosis: a randomized controlled trial
    Hisashi Hidaka
    Department of Gastroenterology, Kitasato University East Hospital, 2 1 1 Asamizodai, Minami Ku, Sagamihara, Kanagawa 252 0380, Japan
    J Gastroenterol 46:1316-23. 2011
    ..The renin-angiotensin system plays an important role in hepatic fibrosis and portal hypertension. We evaluated the long-term effects of olmesartan, an angiotensin type 1 (AT1) receptor blocker, on hemodynamics and liver fibrosis...
  13. ncbi Novel inflammatory biomarkers of portal pressure in compensated cirrhosis patients
    Martina Buck
    Veterans Affairs San Diego Healthcare System, San Diego, CA Department of Medicine, University of California, San Diego, La Jolla, CA Biomedical Sciences Program, University of California, San Diego, La Jolla, CA
    Hepatology 59:1052-9. 2014
    ..Our diagnostic test was not efficient in predicting HVPG ≥ 12 mmHg...
  14. ncbi Tempol administration, a superoxide dismutase mimetic, reduces hepatic vascular resistance and portal pressure in cirrhotic rats
    Héctor García-Calderó
    Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, University of Barcelona, Spain
    J Hepatol 54:660-5. 2011
    ..contributes to increase intrahepatic vascular resistance to portal blood flow and as a consequence portal pressure. We aimed to evaluate whether a strategy directed to reduce superoxide using tempol, a small membrane ..
  15. ncbi Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection
    Thomas Reiberger
    Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria
    Clin Gastroenterol Hepatol 9:602-8.e1. 2011
    ..There are limited data on the efficacy and safety of antiviral therapy in patients with hepatitis C virus (HCV)-related cirrhosis, particularly on the impact of portal hypertension...
  16. ncbi Salvianolic acid B lowers portal pressure in cirrhotic rats and attenuates contraction of rat hepatic stellate cells by inhibiting RhoA signaling pathway
    Hong Xu
    Institute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China
    Lab Invest 92:1738-48. 2012
    ..Liver cirrhosis was induced in rats by peritoneal injection of dimethylnitrosamine and the portal pressure was measured. HSCs contraction was evaluated by collagen gel contraction assay...
  17. ncbi Adenoviral dominant-negative soluble PDGFRβ improves hepatic collagen, systemic hemodynamics, and portal pressure in fibrotic rats
    V Reichenbach
    Biochemistry and Molecular Genetics Service, Hospital Clínic Provincial de Barcelona, IDIBAPS, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, University of Barcelona, Barcelona, Spain
    J Hepatol 57:967-73. 2012
    ..Thereafter, we investigated the effects produced by an adenovirus encoding a dominant-negative soluble PDGFRβ (sPDGFRβ) on hemodynamic parameters, PDGFRβ signaling pathway, and fibrosis...
  18. ncbi A comparison of islet autotransplantation with allotransplantation and factors elevating acute portal pressure in clinical islet transplantation
    Toshiyasu Kawahara
    Department of Surgery, University of Alberta, 2D4 44 Walter C Mackenzie Centre, Edmonton, AB, T6G 2B7, Canada
    J Hepatobiliary Pancreat Sci 19:281-8. 2012
    Acute portal pressure rise is occasionally observed during intraportal islet infusion, especially in islet autotransplantation (IAT) where tissue purification is rarely applied...
  19. ncbi Chronic administration of ursodeoxycholic acid decreases portal pressure in rats with biliary cirrhosis
    Ying Ying Yang
    Division of General Medicine, Department of Medicine, Taipei Veterans General Hospital, Taipei 11217, Taiwan
    Clin Sci (Lond) 116:71-9. 2009
    ..The results showed that portal pressure and IHR, hepatic levels of PIIINP, hepatic collagen deposition, mRNA expression of PIIIP-alpha1 and TGF-beta1,..
  20. ncbi Review article: the therapeutic and prognostic benefit of portal pressure reduction in cirrhosis
    C K Triantos
    Division of Gastroenterology, Department of Internal Medicine, University Hospital, Patras, Greece
    Aliment Pharmacol Ther 28:943-52. 2008
    ..Hepatic venous pressure gradient (HVPG) measurement is not a routinely used technique, despite its therapeutic and prognostic value...
  21. pmc The extent of the collateral circulation influences the postprandial increase in portal pressure in patients with cirrhosis
    Agustin Albillos
    Hospital Universitario Ramon y Cajal, Universidad de Alcala, Madrid, Spain
    Gut 56:259-64. 2007
    In cirrhosis, repeated flares of portal pressure and collateral blood flow provoked by postprandial hyperaemia may contribute to variceal dilation and rupture.
  22. ncbi Pharmacological reduction of portal pressure and long-term risk of first variceal bleeding in patients with cirrhosis
    Juan Turnes
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut de Malalties Digestives, Hospital Clinic, IDIBAPS, University of Barcelona, Villaroel 170, 08036 Barcelona, Spain
    Am J Gastroenterol 101:506-12. 2006
    ..The aim of this study was to evaluate whether this protective effect is maintained in the long term and if it extends to other portal hypertension complications...
  23. ncbi ADMA correlates with portal pressure in patients with compensated cirrhosis
    F Vizzutti
    Dipartimento di Medicina Interna, Universita degli Studi di Firenze, Florence, Italy
    Eur J Clin Invest 37:509-15. 2007
    ..We therefore investigated the possible implication of ADMA in chronic liver diseases-induced portal hypertension...
  24. ncbi Captopril reduces portal pressure effectively in portal hypertensive patients with low portal venous velocity
    Soon Koo Baik
    Department of Internal Medicine, Wonju Christian Hospital, Yonsei University Wonju College of Medicine, 162 Ilsan dong, 220 701 Wonju, South Korea
    J Gastroenterol 38:1150-4. 2003
    The effect of an angiotensin II blockade in lowering the portal pressure in patients with liver cirrhosis and portal hypertension is controversial...
  25. ncbi Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial
    Juan G Abraldes
    Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Spain
    Gastroenterology 136:1651-8. 2009
    ..This randomized controlled trial evaluated the effects of continuous simvastatin administration on the hepatic venous pressure gradient (HVPG) and its safety in patients with cirrhosis and portal hypertension...
  26. ncbi Superoxide dismutase gene transfer reduces portal pressure in CCl4 cirrhotic rats with portal hypertension
    B Laviña
    Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic, Barcelona, Spain
    Gut 58:118-25. 2009
    ..NO scavenging by superoxide (O(2)(-)) further contributes to a reduction of NO bioavailability in cirrhotic livers...
  27. ncbi Recent variceal bleeding: Doppler US hepatic vein waveform in assessment of severity of portal hypertension and vasoactive drug response
    Soon Koo Baik
    Department of Internal Medicine, Yonsei University Wonju College of Medicine, 162 Ilsan dong, Wonju 220 701, South Korea
    Radiology 240:574-80. 2006
    ..To prospectively evaluate both the correlation between abnormal Doppler ultrasonography (US) hepatic vein waveforms and the hepatic venous pressure gradient (HVPG) and the response to drug treatment in patients with cirrhosis...
  28. ncbi Acute and 7-day portal pressure response to carvedilol and propranolol in cirrhotics
    Binay K De
    Department of Medicine, Istitute of Post Graduate Medical Education and Research, Calcutta, India
    J Gastroenterol Hepatol 17:183-9. 2002
    ..Carvedilol, a non-selective beta- and alpha-1 blocking agent, has portal hypotensive action. This study evaluates the acute and 7-day response to carvedilol, and compares it to that of propranolol...
  29. ncbi Assessment of the agreement between wedge hepatic vein pressure and portal vein pressure in cirrhotic patients
    U Thalheimer
    Liver Transplantation and Hepatobiliary Medicine Unit, Royal Free Hospital, Pond Street, NW3 2QG London, UK Internal Medicine Dept, Policlinico G B Rossi, Piazzale L A Scuro, Verona, Italy
    Dig Liver Dis 37:601-8. 2005
    Measuring wedged hepatic venous pressure and hepatic venous pressure gradient as indices of portal pressure is being increasingly used in assessing the prognosis and response to pharmacological treatment for portal hypertension in ..
  30. ncbi NCX-1000, a nitric oxide-releasing derivative of UDCA, does not decrease portal pressure in patients with cirrhosis: results of a randomized, double-blind, dose-escalating study
    Annalisa Berzigotti
    Hepatic Hemodynamics Laboratory, Hospital Clinic IDIBAPS, University of Barcelona, Barcelona, Spain
    Am J Gastroenterol 105:1094-101. 2010
    ..This study was aimed at testing the efficacy and tolerability of this compound in patients with cirrhosis and portal hypertension...
  31. ncbi Kupffer cell activation by hydrogen peroxide: a new mechanism of portal pressure increase
    Christian J Steib
    Department of Medicine II Gastroenterology and Hepatology, University of Munich Grosshadern, Munich, Germany
    Shock 33:412-8. 2010
    ..targets of vasoconstrictors involved in the regulation of intrahepatic microcirculation and therefore portal pressure. The effects of hydrogen peroxide (H2O2), xanthine/xanthine oxidase or a thromboxane (TX) analogue (U46619; 0...
  32. ncbi Current concepts on the pathophysiology of portal hypertension
    Aina Rodriguez-Vilarrupla
    Hepatic Hemodynamic Laboratory, Liver Unit Institut Malalties Digestives I Metabòliques, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, CIBER Enfermedades Hepáticas y Digestivas, University of Barcelona, Spain
    Ann Hepatol 6:28-36. 2007
    ..When the portal pressure gradient (the difference between pressures in the portal and the inferior vena cava veins: normal value below ..
  33. ncbi Measurement of portal pressure: when, how, and why to do it
    Roberto Groszmann
    Digestive Diseases 111H, Veterans Affairs, Connecticut Healthcare System, 950 Campbell Avenue, West Haven, CT 06516, USA
    Clin Liver Dis 10:499-512, viii. 2006
    ..The ease, accuracy, and safety of HVPG measurement has made it a valuable tool in the research arena and, increasingly, in clinical practice...
  34. ncbi Science to practice: Noninvasive assessment of portal hypertension--can US aid in the prediction of portal pressure and monitoring of therapy?
    Ethan J Halpern
    Department of Radiology, Thomas Jefferson University Hospital, Jefferson Prostate Diagnostic Center, 132 S 10th St, Philadelphia, PA 19107 5244, USA
    Radiology 240:309-10. 2006
    ..Ongoing research suggests that microbubble contrast agents may enable a more quantitative noninvasive estimate of intravascular pressures with US...
  35. ncbi Somatostatin treatment and risk stratification by continuous portal pressure monitoring during acute variceal bleeding
    C Villanueva
    Department of Gastroenterology, Hospital de la Santa Creu i Sant Pau, Avgda Sant Antoni Ma Claret, 167, 08025 Barcelona, Spain
    Gastroenterology 121:110-7. 2001
    ..Whether somatostatin can suppress these increments is unknown. This study monitored somatostatin effects on HVPG during acute bleeding and assessed whether the changes affect outcome...
  36. pmc Altered blood-brain barrier permeability in rats with prehepatic portal hypertension turns to normal when portal pressure is lowered
    Francisco Eizayaga
    Laboratory of Portal Hypertension, School of Pharmacy and Biochemistry, University of Buenos Aires, Junin 956, C P 1113, Ciudad Autonoma de Buenos Aires, Republica Argentina
    World J Gastroenterol 12:1367-72. 2006
    To study the blood-brain barrier integrity in prehepatic portal hypertensive rats induced by partial portal vein ligation,at 14 and 40 d after ligation when portal pressure is spontaneously normalized.
  37. pmc In vivo gene transfer of endothelial nitric oxide synthase decreases portal pressure in anaesthetised carbon tetrachloride cirrhotic rats
    M Van de Casteele
    Laboratory of Hepatology, University Hospital Gasthuisberg, Leuven, B 3000 Leuven, Belgium
    Gut 51:440-5. 2002
    ..Enhanced endothelin-1 and decreased activity of hepatic constitutive endothelial nitric oxide synthase (NOS 3) was reported in carbon tetrachloride (CCl(4)) cirrhotic rat liver...
  38. ncbi [Effect and mechanism of salvianolic acid B in attenuating elevated portal pressure in a rat model of portal hypertension induced by endothelin-1]
    Yang Zhou
    Institute of Liver Diseases, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
    Zhong Xi Yi Jie He Xue Bao 5:61-4. 2007
    ..To investigate the effects of salvianolic acid B (SA-B) on portal hypertension induced by endothelin-1 in rats...
  39. ncbi The relationship between liver function and portal pressure: what comes first, the chicken or the egg?
    Christos Triantos
    J Hepatol 42:146-7; author reply 147-8. 2005
  40. ncbi High-density lipoprotein administration attenuates liver proinflammatory response, restores liver endothelial nitric oxide synthase activity, and lowers portal pressure in cirrhotic rats
    Dominique Thabut
    INSERM, U773, Centre de Recherche Biomedicale Bichat Beaujon CRB3, Paris 75018, France
    Hepatology 46:1893-906. 2007
    ..The portal pressure was measured. The plasma HDL levels were significantly lower in cirrhotic rats than in control rats...
  41. ncbi Should we routinely measure portal pressure in patients with cirrhosis, using hepatic venous pressure gradient (HVPG) as a guide for prophylaxis and therapy of bleeding and rebleeding? No
    Ulrich Thalheimer
    The Sheila Sherlock Liver Centre, Royal Free Hospital, London, UK
    Eur J Intern Med 22:5-7. 2011
    ..This has diminished its applicability. Combining its use with transjugular liver biopsy and using the prognostic value of HVPG may help encourage its use...
  42. ncbi Effect of carvedilol on portal pressure estimated by hepatic vein Doppler ultrasound waveform and damping index in cirrhotic patients
    Qurban Hussain
    Medical ICU, Jinnah Postgraduate Medical Centre, Karachi
    J Coll Physicians Surg Pak 20:586-9. 2010
    To assess the effect of Carvedilol in reducing portal pressure estimated non-invasively by studying Doppler ultrasound waveforms (DUS) and hepatic vein Damping Index (DI).
  43. ncbi Chronic administration of losartan, an angiotensin II receptor antagonist, is not effective in reducing portal pressure in patients with preascitic cirrhosis
    Dhiraj Tripathi
    Liver Unit, Department of Medicine, Royal Infirmary, Edinburgh, UK
    Am J Gastroenterol 99:390-4. 2004
    ..We aimed to study both the systemic and portal hemodynamics, and tolerability after chronic administration of losartan, an ANG II receptor antagonist...
  44. ncbi Right atrial pressure is not adequate to calculate portal pressure gradient in cirrhosis: a clinical-hemodynamic correlation study
    Vincenzo La Mura
    Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBERehd, Barcelona, Spain
    Hepatology 51:2108-16. 2010
    ..HVPG), the difference between wedge and free hepatic venous pressure, is the preferred method for estimating portal pressure. However, it has been suggested that hepatic atrial pressure gradient (HAPG)--the gradient between wedge ..
  45. ncbi Mild increases in portal pressure upregulate vascular endothelial growth factor and endothelial nitric oxide synthase in the intestinal microcirculatory bed, leading to a hyperdynamic state
    Juan G Abraldes
    Hepatic Hemodynamic Laboratory, Veterans Affairs Connecticut Healthcare System, Digestive Disease 111H, 950 Campbell Ave, New Haven, CT 06516, USA
    Am J Physiol Gastrointest Liver Physiol 290:G980-7. 2006
    ..with advanced portal hypertension (PHT), but the initial mechanisms and the magnitude of increase in portal pressure required to trigger NO production are not known...
  46. ncbi Sustained rise of portal pressure after sclerotherapy, but not band ligation, in acute variceal bleeding in cirrhosis
    Alec Avgerinos
    2nd Department of Gastroenterology, Athens University, Evangelismos Hospital, Athens, Greece
    Hepatology 39:1623-30. 2004
    During variceal bleeding, several factors may increase portal pressure, which in turn may precipitate further bleeding...
  47. ncbi Renovascular impedance correlates with portal pressure in patients with liver cirrhosis
    Annalisa Berzigotti
    Dipartimento di Medicina Interna, Cardioangiologia, Epatologia, Universita di Bologna, Policlinico S Orsola Malpighi, Via Albertoni 15 40138 Bologna, Italy
    Radiology 240:581-6. 2006
    ..with liver cirrhosis, the correlation between the renovascular impedance measured by using color flow and pulsed wave Doppler ultrasonography (US) and the portal pressure measured by using the hepatic venous pressure gradient (HVPG).
  48. ncbi The influence of endoscopic variceal ligation on the portal pressure gradient in cirrhotics
    Julio C Pereira-Lima
    Department of Gastroenterology and Hepatology, Porto Alegre School of Medical Sciences FFFCMPA, Santa Casa University Hospital, Porto Alegre, Brazil
    Hepatogastroenterology 50:102-6. 2003
    ..The aim of this study is to verify the impact of the eradication of esophageal varices by endoscopic ligation on the portal pressure gradient, worsening of portal hypertensive gastropathy and development of fundal varices.
  49. ncbi Prognostic value of portal pressure at the time of Kasai operation in patients with biliary atresia
    Matthieu Duché
    Paediatric Surgery, Hepatology, Intensive Care, Pathology and Radiology Units, Bicetre University Hospital, Paris, France
    J Pediatr Gastroenterol Nutr 43:640-5. 2006
    To examine the prognostic value of portal pressure at the time of Kasai operation in patients with biliary atresia (BA).
  50. ncbi Regenerative response in the pig liver remnant varies with the degree of resection and rise in portal pressure
    Kim Erlend Mortensen
    Department of Digestive Surgery, University Hospital of Northern Norway, Tromsø, Norway
    Am J Physiol Gastrointest Liver Physiol 294:G819-30. 2008
    ..Six pig livers were resected with 62% (low portal pressure resection) and 75% (high portal pressure resection), resulting in a portal venous pressure increase from a ..
  51. ncbi Preservation of portal pressure improves growth and metabolic profile in the male portacaval-shunted rat
    Srinivasan Dasarathy
    Schwartz Center for Metabolism and Nutrition, Division of Gastroenterology, Cleveland, Ohio, USA
    Dig Dis Sci 47:1936-42. 2002
    ..The severity of these abnormalities is variable and may be related to a number of factors, including portal pressure, portosystemic shunting, dietary intake, and how efficiently food is used...
  52. ncbi Patency of stents covered with polytetrafluoroethylene in patients treated by transjugular intrahepatic portosystemic shunts: long-term results of a randomized multicentre study
    Christophe Bureau
    Federation Digestive Purpan, Service Hepato Gastro Enterologie CHU Toulouse, Toulouse, France
    Liver Int 27:742-7. 2007
    ..In conclusion, the improvement in TIPS patency by using covered prostheses is maintained over time with a decreased risk of encephalopathy, while the risk of death was not increased...
  53. ncbi Prevention of hepatic infarction as acute-phase complication of TIPS by temporary balloon occlusion in a patient with primary myelofibrosis
    Satoshi Kobayashi
    Department of Radiology, Kanazawa University School of Medicine, Ishikawa, Japan
    Radiat Med 22:432-6. 2004
    ..In such cases, temporary balloon occlusion of TIPS is an effective therapeutic method, probably as a result of inducing the development of arterial compensation through the peribiliary plexus...
  54. ncbi Optimal portal venous circulation for liver graft function after living-donor liver transplantation
    Shintaro Yagi
    First Department of Surgery, Mie University School of Medicine, Tsu City, Japan
    Transplantation 81:373-8. 2006
    ..We investigated optimal portal venous circulation for liver graft function after LDLT in adult recipients retrospectively...
  55. ncbi Postprandial splanchnic haemodynamic changes in patients with liver cirrhosis and patent paraumbilical vein
    Annalisa Berzigotti
    Dipartimento di Medicina Interna, Cardioangiologia, Epatologia, Universita di Bologna, Bologna, Italy
    Eur J Gastroenterol Hepatol 16:1339-45. 2004
    ..We aimed to study the postprandial modifications of splanchnic circulation in patients with a patent paraumbilical vein (PUV)...
  56. ncbi [Intra-operative evaluation of portal pressure and immediate results of surgical treatment of portal hypertension in schistosomotic patients submitted to esophagogastric devascularization with splenectomy]
    Walter De Biase da Silva-Neto
    Departamento de Cirurgia, Faculdade de Medicina, Universidade Federal de Goias, Goiania, GO
    Arq Gastroenterol 41:150-4. 2004
    ..The hemodynamic alterations after surgical treatment and its possible influence on the outcome are not well established...
  57. ncbi Improvement of portal hypertension and hepatic blood flow in cirrhotic rats by oestrogen
    M Sakamoto
    Second Department of Medicine, Kurume University School of Medicine, 67 Asahi Machi, Kurume 830 0011, Japan
    Eur J Clin Invest 35:220-5. 2005
    ..In this study, we investigated the effects of oestrogen on nitric oxide synthase activity and nitric oxide production using the cirrhotic rat liver...
  58. ncbi Fate of bradykinin on the rat liver when administered by the venous or arterial route
    Luciana Gioli-Pereira
    Department of Biochemistry, Sao Paulo Federal University, Sao Paulo, Brazil
    J Gastroenterol Hepatol 20:463-73. 2005
    ..Bradykinin (BK) infused into the portal vein elicits a hypertensive response via the B2 receptor (B2R) and is efficiently hydrolyzed by the liver. Our purpose was to characterize the mechanism of interaction between BK and the liver...
  59. ncbi Pathophysiology of portal hypertension in HCV-related cirrhosis. Putative role of assessment of portal pressure gradient in Peginterferon-treated patients
    L Ratti
    Department of Clinical Medicine, Prevention and Applied Biotechnical Technologies, Azienda Ospedaliera San Gerardo and Milano Bicocca University, Via Donizetti 106 20052 Monza, Milano, Italy
    Dig Liver Dis 37:886-93. 2005
    ..in the clinical assessment of portal hypertension and its management, could provide information on the portal pressure-lowering effects of interferon treatment affecting the fibrosis score...
  60. ncbi Relationship between the degree of portal hypertension and the onset of spontaneous bacterial peritonitis in patients with cirrhosis
    Thomas Sersté
    Department of Gastroenterology, ULB Erasme University Hospital, Brussels, Belgium
    Acta Gastroenterol Belg 69:355-60. 2006
    ..The aim of this study was to test the hypothesis that an association exists between the degree of portal hypertension and the occurrence of SBP...
  61. ncbi Value of the hepatic venous pressure gradient to monitor drug therapy for portal hypertension: a meta-analysis
    Agustin Albillos
    Servicio de Gastroenterologia, Hospital Ramon y Cajal, Madrid, Spain
    Am J Gastroenterol 102:1116-26. 2007
    ..Our aim was to establish whether target HVPG reduction predicts variceal bleeding in cirrhotic patients receiving variceal bleeding prophylaxis...
  62. ncbi A novel endovascular adjustable polytetrafluoroethylene-covered stent for the management of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt
    Joshua L Weintraub
    Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029, USA
    J Vasc Interv Radiol 18:563-6. 2007
    ..This method was successful in narrowing the patient's TIPS, acutely increasing the portosystemic gradient and reversing the hepatic encephalopathy...
  63. ncbi A 3-month course of long-acting repeatable octreotide (sandostatin LAR) improves portal hypertension in patients with cirrhosis: a randomized controlled study
    Laurent Spahr
    Transplantation Unit, University Hospital, Geneva, Switzerland
    Am J Gastroenterol 102:1397-405. 2007
    ..Information on long-term effects of octreotide is limited and controversial. We evaluated portal and systemic hemodynamics following a prolonged administration of long-acting octreotide in patients with cirrhosis...
  64. ncbi [Laparoscopic devascularization of the stomach and the abdominal esophagus with the LigaSure instrument in a porcine model]
    Laszlo Benko
    Pécsi TudomBnyegyetem, Általános Orvostudományi Kar, Sebészeti Oktaó6 és Kutató Intézet
    Magy Seb 59:45-9. 2006
    ..In this study we proved the feasibility of a new minimally invasive procedure for the devascularisation of the proximal stomach and the abdominal esophagus to prevent recurrent variceal bleeding in portal hypertension in a new animal model...
  65. ncbi Effects of splenic artery occlusion on portal pressure in patients with cirrhosis and portal hypertension
    Angelo Luca
    Diagnostic and Interventional Radiology, Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione, Palermo, Italy
    Liver Transpl 12:1237-43. 2006
    ..In 15 cirrhotic patients, portal pressure gradient (PPG) was measured just before inserting a transjugular intrahepatic portosystemic shunt (TIPS), in ..
  66. ncbi [Measurement of portal pressure: a clinical parameter or research tool?]
    L Ruiz-del-Arbol Olmos
    Gastroenterol Hepatol 28:237-9. 2005
  67. ncbi Losartan in preascitic cirrhosis
    Gustavo Castano
    Am J Gastroenterol 99:2282-3. 2004
  68. ncbi Covered transjugular intrahepatic portosystemic stents maintain lower portal pressure and require fewer reinterventions than uncovered stents
    J Ockenga
    Medizinische Klinik mit Schwerpunkt Gastroenterologie, Hepatologie und Endokrinologie, Charite Universitatsmedizin Berlin, Germany
    Scand J Gastroenterol 39:994-9. 2004
    ..The purpose of this study was to evaluate the patency, functional and haemodynamic results of expanded-polytetrafluoroethylene (ePTFE)-covered transjugular intrahepatic portosystemic shunts in patients with liver cirrhosis...
  69. ncbi Different haemodynamic effects of a single dose of long-acting isosorbide-5-mononitrate in healthy subjects and patients with cirrhotic portal hypertension
    F Piscaglia
    Division of Internal Medicine, Department of Internal Medicine and Gastroenterology, University of Bologna, Azienda S Orsola Malpighi, Via Albertoni 15, 40138 Bologna, Italy
    Dig Liver Dis 36:594-602. 2004
    ..The action pathways of nitrates are hypothesised to be deranged in cirrhosis...
  70. ncbi Hepatic venous pressure gradient and outcomes in cirrhosis
    Cristina Ripoll
    Hepatology and Liver Transplant Unit, Department of Digestive Diseases Hospital Gregorio Marañón and Ciber EHD, Madrid, Spain
    J Clin Gastroenterol 41:S330-5. 2007
    ..Hepatic venous pressure gradient (HVPG), as an estimation of portal pressure, has been associated to the development of these complications...
  71. ncbi Hepatic venous pressure in practice: how, when, and why
    Julio D Vorobioff
    University of Rosario Medical School, Rosario, Argentina
    J Clin Gastroenterol 41:S336-43. 2007
    ....
  72. ncbi Correlations of portal hypertensive gastropathy of hepatitis B cirrhosis with other factors
    Wei dong Pan
    Department of General Surgery, Third Affiliated Hospital, Zhongshan University, Guangzhou 510630, China
    Hepatobiliary Pancreat Dis Int 1:527-31. 2002
    ..To study the clinical relations of portal hypertensive gastropathy (PHG) of hepatitis B cirrhosis to other factors...
  73. ncbi The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension
    Luis Colombato
    Hepatic Hemodynamic Section, Liver Unit, Gastroenterology Department, Buenos Aires British Hospital, Buenos Aires School of Medicine, Buenos Aires University, Buenos Aires, Argentina
    J Clin Gastroenterol 41:S344-51. 2007
    ..TIPS constitutes the most frequently employed tool to achieve portosystemic shunting. TIPS acts by lowering portal pressure, which is the main underlying pathophysiologic determinant of the major complications of cirrhosis...
  74. ncbi Wedged hepatic venous pressure does not reflect portal pressure in patients with cirrhosis and hepatic veno-venous communications
    Yuji Osada
    Department of Internal Medicine, Division of Gastroenterology, Nippon Medical School Hospital, Tokyo, Japan
    Dig Dis Sci 53:7-13. 2008
    ..001). Large porto-systemic collaterals did not affect the relationship. We conclude that HVVC affects the relationship between PVP and WHVP. When WHVP is measured, occluded hepatic venography should be examined to detect HVVC...
  75. ncbi Effect of propranolol and depot lanreotide SR on postprandial and circadian portal haemodynamics in cirrhosis
    P Schiedermaier
    Department of Internal Medicine I, University of Bonn, Germany
    Aliment Pharmacol Ther 18:777-84. 2003
    ..Long-acting somatostatin analogues have been suggested as an alternative to propranolol for the prevention of variceal rebleeding...
  76. ncbi Hepatic flow parameters measured with MR imaging and Doppler US: correlations with degree of cirrhosis and portal hypertension
    Laurence Annet
    Department of Radiology, Universite Catholique de Louvain, St Luc University Hospital, Avenue Hippocrate 10, B 1200 Brussels, Belgium
    Radiology 229:409-14. 2003
    ..To determine the correlations between hemodynamic parameters of hepatic flow measured with magnetic resonance (MR) imaging and Doppler ultrasonography (US) and the severity of cirrhosis and portal hypertension...
  77. pmc Decompensated porto-pulmonary hypertension in a cirrhotic patient with thrombosis of portocaval shunt
    Chiara Giannarelli
    Department of Internal Medicine, University of Pisa, Via Roma 67, Pisa 56126, Italy
    World J Gastroenterol 13:6439-40. 2007
    ..In fact, it has been demonstrated that the increased portal pressure, caused by occlusion of portosystemic shunt, reduces renal plasma flow and increases systemic endothelin-1 ..
  78. ncbi Irbesartan plus low-dose propranolol versus low-dose propranolol alone in cirrhosis: a placebo-controlled, double-blind study
    Michael Schepke
    Department of Internal Medicine I, University of Bonn, Bonn, Germany
    Am J Gastroenterol 103:1152-8. 2008
    Angiotensin II receptor antagonists have been shown to moderately lower portal pressure in some patients with cirrhosis but may have adverse effects on kidney function...
  79. ncbi Noninvasive prediction of clinically significant portal hypertension and esophageal varices in patients with compensated liver cirrhosis
    Annalisa Berzigotti
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut d Investigacions Biomèdiques August Pi i Sunyer IDIBAPS and Centro de Investigación Biomèdica en Red de Enfermedades Hepáticas y Digestivas CIBERehd, University of Barcelona, Barcelona, Spain
    Am J Gastroenterol 103:1159-67. 2008
    ..We aimed to develop a model based on noninvasive variables for the prediction of clinically significant portal hypertension (CSPH) and of esophageal varices (EV) in patients with compensated liver disease...
  80. ncbi Use of portocaval venografts with ameroid constrictor placement and hepatic lobectomy for treatment of intralobular intrahepatic portocaval shunts in four dogs
    Kelly L Gellasch
    Department of Surgical Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI 53706, USA
    J Am Vet Med Assoc 222:455-60, 449. 2003
    ..To maintain portal pressure at an acceptable value after lobectomy, an extrahepatic portocaval shunt vessel can be created by use of an ..
  81. ncbi Effects of prophylactic splenic artery modulation on portal overperfusion and liver regeneration in small-for-size graft
    Yuzo Umeda
    Department of Gastroenterological Transplant Surgery and Surgical Oncology, Okayama University Graduate School of Medicine and Dentistry, Shikata cho, Okayama City, Okayama, Japan
    Transplantation 86:673-80. 2008
    ..Various approaches for portal decompression have been used, but details of their impact on liver regeneration in SFS graft remain unclear. We examined the effect of prophylactic splenic artery modulation (SAM)...
  82. ncbi The molecules: mechanisms of arterial vasodilatation observed in the splanchnic and systemic circulation in portal hypertension
    Yasuko Iwakiri
    Section of Digestive Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06520, USA
    J Clin Gastroenterol 41:S288-94. 2007
    ....
  83. ncbi Hemodynamic effects of propranolol and nitrates in cirrhotics with transjugular intrahepatic portosystemic stent-shunt
    K A Brensing
    Dept of Internal Medicine, University of Bonn, Germany
    Scand J Gastroenterol 37:1070-6. 2002
    ..The combination of tailored TIPS with vasoactive drugs might allow reduction of the rate of subsequent shunt-related sequelae...
  84. pmc Monitoring target reduction in hepatic venous pressure gradient during pharmacological therapy of portal hypertension: a close look at the evidence
    U Thalheimer
    Liver Transplantation and Hepatobiliary Unit, Royal Free Hospital, Pond St, London NW3 2QG, UK
    Gut 53:143-8. 2004
    ..However, the clinical validity and applicability of monitoring for target HVPG reductions is not sufficiently proven and needs to be specifically evaluated in a prospective trial...
  85. ncbi Prevention of recurrent esophageal variceal hemorrhage: review and current recommendations
    David Kravetz
    San Diego Veterans Affairs Medical Center, University of California at San Diego, San Diego, CA 92161, USA
    J Clin Gastroenterol 41:S318-22. 2007
    ..The only difference observed was the higher rate of reintervention observed in the TIPS group to maintain his patency...
  86. ncbi Chronic lymphocytic leukemia with portal hypertension and without liver involvement: a case report underlining the roles of increased spleno-portal blood flow and "protective" sinusoidal vasoconstriction
    J Y Wilputte
    Service de Gastroenterologie, cliniques UCL St Luc, Bruxelles
    Acta Gastroenterol Belg 66:303-6. 2003
    ..This case shows the potential for an increased spleno-poral flow to generate severe portal hypertension likely through a "protective" sinusoidal vasoconstriction...
  87. ncbi [Effects of acute octreotide infusion on renal function in patients with cirrhosis and portal hypertension]
    Guillermo Silva
    Departamento de Gastroenterologia, Clinica Las Condes, Santiago, Chile
    Rev Med Chil 132:144-50. 2004
    ..The consequences of these haemodynamic changes on renal circulation are not well known in cirrhotic patients...
  88. ncbi Hepatic venous pressure gradient does not correlate with the presence and the severity of portal hypertensive gastropathy in patients with liver cirrhosis
    Lia Bellis
    Haemodynamic Unit, Marino General Hospital, Via XXIV Maggio, 00047 Marino, Rome, Italy
    J Gastrointestin Liver Dis 16:273-7. 2007
    ..To evaluate whether the hepatic venous pressure gradient (HVPG) differs between cirrhotic patients with severe portal hypertensive gastropathy (PHG) and those with mild or absent PHG...
  89. ncbi Vascular deterioration in cirrhosis: the big picture
    Jaime Bosch
    Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic IDIBAPS, University of Barcelona and Centro de Investigación Biomédica de Enfermedades Hepáticas y Digestivas Ciberehd, Barcelona, Spain
    J Clin Gastroenterol 41:S247-53. 2007
    ..Advances in the knowledge of the mechanisms of these abnormalities have disclosed new targets for therapy and ultimately improved survival...
  90. ncbi Hemodynamics in the isolated cirrhotic liver
    Alexander Zipprich
    First Department of Medicine, Martin Luther University Halle Wittenberg, Halle, Germany
    J Clin Gastroenterol 41:S254-8. 2007
    Increased intrahepatic resistance is the initial event to the increased portal pressure and development portal hypertension in cirrhosis...
  91. ncbi Early and long-term clinical and radiological follow-up results of expanded-polytetrafluoroethylene-covered stent-grafts for transjugular intrahepatic portosystemic shunt procedures
    Geert Maleux
    Department of Radiology, University Hospitals Gasthuisberg, Herestraat 49, Leuven, Belgium
    Eur Radiol 14:1842-50. 2004
    ..The incidence of TIPS-induced hepatic encephalopathy is acceptable...
  92. ncbi Molecular mechanisms of increased intrahepatic resistance in portal hypertension
    Vijay Shah
    Gastrointestinal Research Unit and Advanced Liver Disease Study Group, Mayo Clinic, Rochester, MN, USA
    J Clin Gastroenterol 41:S259-61. 2007
    ..This review will focus on these processes within the intrahepatic circulation, a circulatory bed whose study, that Dr Roberto Groszmann has pioneered...
  93. ncbi Portal hypertension and blood viscosity
    Emanuel Sikuler
    Department of Medicine B, Faculty of Health Sciences, The Soroka Medical Center, Ben Gurion University of the Negev, Beer Sheva, Israel
    J Clin Gastroenterol 41:S262-5. 2007
    Previous studies, exploring the effect of blood viscosity on portal pressure in portal hypertensive humans and animal models, have shown conflicting results...
  94. ncbi Combined devascularization and proximal splenorenal shunt: is this a better option than either procedure alone?
    Chong En Xu
    The Queensland Liver Transplant Service, Princess Alexandra Hospital, Ipswich Road, Woolloongabba QLD 4102, Australia
    J Hepatobiliary Pancreat Surg 11:129-34. 2004
    ....
  95. ncbi Preventing the development of varices in cirrhosis
    Guadalupe Garcia-Tsao
    Section of Digestive Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06510, USA
    J Clin Gastroenterol 41:S300-4. 2007
    ..Nonselective beta-adrenergic blockers decrease portal pressure and are effective in preventing variceal hemorrhage...
  96. ncbi The treatment of acute variceal bleeding
    Juan G Abraldes
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut Malalties Digestives i Metabòliques, Hospital Clinic, University of Barcelona, Barcelona, Spain
    J Clin Gastroenterol 41:S312-7. 2007
    ..This paper reviews the most recent advancements in the general management and hemostatic treatments of acute variceal bleeding...
  97. ncbi Preventing first variceal hemorrhage in cirrhosis
    Agustin Albillos
    Servicio de Gastroenterologia, Hospital Universitario Ramon y Cajal, CIBERehd, Unidad I D Asociada al Centro Nacional de Biotecnología CSIC, Universidad Alcala, Madrid, Spain
    J Clin Gastroenterol 41:S305-11. 2007
    ..However, no study has yet demonstrated that banding as rescue therapy in nonresponders lowers the risk of first bleeding and improves survival...
  98. ncbi Portal blood flow, effective hepatic blood flow, and outcome after partial portal decompression
    Alexander S Rosemurgy
    Department of Surgery, University of South Florida College of Medicine, Tampa, Florida 33601, USA
    J Surg Res 117:64-70. 2004
    ..As practicing surgeons, we have prospered by being raised on the shoulders of giants in Surgery that trained and inspired us. Dr. David B. Skinner was such a giant...
  99. ncbi Effects of tumor necrosis factor, endothelin and nitric oxide on hyperdynamic circulation of rats with acute and chronic portal hypertension
    Ji Jian Wang
    Department of General Surgery, Second Affiliated Hospital, Chongqing University of Medical Sciences, 74 Linjing Road, Chongqing 400010, China
    World J Gastroenterol 10:689-93. 2004
    ..To evaluate the effect of tumor necrosis factor (TNF), endothelin (ET) and nitric oxide (NO) on hyperdynamic circulation (HC) of rats with acute and chronic portal hypertension (PHT)...
  100. ncbi Effects of leukotrienes and the thromboxane A2 analogue U-46619 in isolated perfused rat liver. Metabolic, hemodynamic and ion-flux responses
    D Haussinger
    Medizinische Universitätsklinik Freiburg im Breisgau
    Biol Chem Hoppe Seyler 369:97-107. 1988
    ..of hepatic glucose output, a slight decrease of 14CO2 production from [1-14C] glutamate, an increase of portal pressure and an inhibition of hepatic oxygen uptake...
  101. pmc Expression of TNF-alpha and VEGF in the esophagus of portal hypertensive rats
    Zhao Hui Yin
    Division of Transplantation Surgery, Center for Surgical Sciences, Karolinska University Hospital, Huddinge B56, S 141 86 Stockholm, Sweden
    World J Gastroenterol 11:1232-6. 2005
    ..To investigate the expression of tumor necrosis factor-alpha (TNF-alpha) and vascular endothelial growth factor (VEGF) in the development of esophageal varices in portal hypertensive rats...

Research Grants24

  1. Carbamazepine for severe liver disease due to antitrypsin deficiency
    David H Perlmutter; Fiscal Year: 2012
    ..fibrosis in AT- deficient individuals with severe liver disease;3) Determine whether CBZ treatment reduces portal pressure in AT-deficient individuals with severe liver disease...
  2. LDLT: Diagnostic Markers of Liver Regeneration to Predict Outcomes
    Elizabeth A Pomfret; Fiscal Year: 2013
    ..The incidence will be determined by direct measurement of portal pressure and procedures to reduce pressures will be investigated...
  3. Molecular Mechanisms of Portal Hypertension
    Vijay H Shah; Fiscal Year: 2012
    ..of portal hypertension are associated with increased sinusoidal coverage by HSC and an ensuing increase in portal pressure, pointing to an in vivo relevance of the proposed pathways...
  4. A2ALL Cohort Study: Pyschosocial and Surgical Outcomes
    Abhinav Humar; Fiscal Year: 2013
    ..the development of small-for-size-syndrome (SFSS) in recipients after ALDLT - most specifically the impact of portal pressure measurements and inflow modification on the risk for SFSS...
  5. Quantitative Hemodynamics of the Liver with 4D Flow MRI
    Oliver Wieben; Fiscal Year: 2013
    ..Most therapies reduce portal pressure through reductions in the flow to the liver (eg...
  6. CIRRHOSIS AND ITS COMPLICATIONS
    Guadalupe Garcia Tsao; Fiscal Year: 2009
    ..contributed to the completion of a long trial of beta-blocker in the prevention of varices and identified portal pressure as an important predictor of cirrhosis decompensation not only in all cirrhotic patients, but particularly in ..
  7. SPLANCHNIC HEMODYNAMICS IN PORTAL HYPERTENSION
    JAMES SITZMANN; Fiscal Year: 1992
    ..Systemic and portal PGI2/glucagon and splanchnic blood flow will be measured. The effect of normalization of portal pressure (portosystemic shunt) on the hyperemia of human portal hypertension will be studied...
  8. PLATELET ACTIVATING FACTOR AND THROMBOXANES IN LIVER
    Rory Fisher; Fiscal Year: 1993
    ..in vivo will characterize the effects of the se mediators on hepatic hemodynamics by measurements of hepatic portal pressure and hepatic portal and arterial flows...
  9. MODULATORY NETWORK COMPONENETS IN JAPONICA
    GLENN OLDS; Fiscal Year: 1990
    ..becomes chronic, a beneficial immunologic adjustment occurs that results in smaller egg granuloma and lower portal pressure. This process, termed modulation is essential to our understanding of disease in man since the majority of ..
  10. INTESTINE IN CHRONIC PORTAL HYPERTENSION
    JOSEPH BENOIT; Fiscal Year: 2004
    ..a condition that results from cirrhosis or intrahepatic liver disease, is characterized by an elevated portal pressure, portosystemic shunting, an intense intestinal vasodilation and decreased vasoconstrictor responsiveness...
  11. ICOS-B7h in Islet Transplant Rejection and Autoimmunity
    Andrew Shapiro; Fiscal Year: 2004
    ....
  12. TRIAL OF ANTI-TNF ALPHA IN ISLET TRANSPLANTATION
    Andrew Shapiro; Fiscal Year: 2002
    ....
  13. Measurement & modulation of the mutation rate in humans
    David Araten; Fiscal Year: 2007
    ..These studies will begin to elucidate the relationship between f and cancer risk and provide a highly relevant in vitro parameter with which to evaluate chemoprevention. ..
  14. US Prostate Cancer Detection with Dutasteride Pretreatment
    Ethan Halpern; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  15. NO production and S-nitrosylation in liver vasculature
    Yasuko Iwakiri; Fiscal Year: 2008
    ..The School of Medicine has pledged protected time for the candidate during this further training period prior to functioning as an independent investigator. ..
  16. Molecular Mechanisms of Portal Hypertension
    Vijay Shah; Fiscal Year: 2007
    ..of portal hypertension are associated with increased sinusoidal coverage by HSC and an ensuing increase in portal pressure, pointing to an in vivo relevance of the proposed pathways...
  17. Perfusion preservation solution for recovery of Donation by Cardiac Death livers
    Charles Lee; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable]..
  18. Pathophysiological Interpretations of Dynamic PET/CT of Molecular Liver Biology
    Susanne Keiding; Fiscal Year: 2010
    ..This will lead to improved diagnosis and treatment of the large groups of patients with liver disease and cancer in the liver. ..
  19. Short-term mesenteric lymphatic adaptation to trauma-related intestinal edema
    Emily Wilson; Fiscal Year: 2010
    ..abstract_text> ..
  20. Inhibition of TNF in Patients with Alcoholic Hepatitis
    Vijay Shah; Fiscal Year: 2005
    ..abstract_text> ..
  21. Failure of FasL Mediated Pathways in Tumor Angiogenesis
    Vijay Shah; Fiscal Year: 2006
    ..These insights may lead to novel and effective therapeutic strategies that target this pathway to prevent angiogenesis, and thereby prevent colorectal tumor development growth and spread. ..
  22. REG OF NITRIC OXIDE PRODUCT IN THE HEPATIC CIRCULATION
    Vijay Shah; Fiscal Year: 2002
    ..Intrahepatic vasoconstriction contributes to the development of an increase in portal pressure in hepatic cirrhosis...
  23. Endothelial Nitric Oxide Synthase & Portal Hypertension
    Vijay Shah; Fiscal Year: 2002
    ..further delineate the regulatory mechanisms of eNOS derived NO as they relate to hepatic vascular biology and portal pressure regulation, and thereby progress our understanding of the pathogenesis and treatment of portal hypertension...
  24. ESOPHAGEAL VARICES BY B-ADRENERGIC BLOCKERS
    Roberto Groszmann; Fiscal Year: 2003
    ..Non-selective beta- adrenergic blockers decrease portal pressure and have been shown to prevent the first variceal hemorrhage in patients with cirrhosis and varices...